申请人:Aldeyra Therapeutics, Inc.
公开号:US10543181B2
公开(公告)日:2020-01-28
The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
本发明通过使用伯胺清除有毒的醛,如 MDA 和 HNE,从而治疗、预防和/或降低醛毒性与发病机制有关的疾病、失调或病症的风险,包括眼部疾病、皮肤疾病、与起泡剂的伤害作用有关的病症,以及自身免疫性、炎症性、神经性和心血管疾病。